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The time is right to look at new ways of reducing 
mortality among people who use illicit drugs. 
Across the UK, we are seeing record levels of 
drug-related deaths. These deaths often occur 
among people who use heroin, as well as alcohol 
and tobacco. The appearance of synthetic opioids 
like fentanyl and carfentanil in the UK drug 
markets threatens to cause even more harm. 
Many of the most vulnerable people are not well 
served by existing models of treatment. So we 
need new ways of engaging these people in 
services that can save their lives. The need for 
drug consumption rooms is urgent.
As this report shows, providing facilities where 
people can use illicitly purchased heroin under the 
supervision of trained staff has saved many lives 
in the countries where they already exist. There 
has never been a death from overdose in a drug 
consumption room. Although many overdose 
events have occurred, the presence of trained 
staff and swift delivery of oxygen and naloxone 
prevents death. Such facilities do not increase 
drug use or crime in their neighbourhoods. Rather, 
they reduce risks related to public injecting and 
discarded needles. They form a valuable part of 
the mix of interventions that are required to reduce 
deaths. This also includes opioid substitution 
therapy of optimal dosage and duration, wider 
provision of naloxone, heroin-assisted treatment 
and investment in welfare, social and mental 
health services.
The legal barriers to the establishment of drug 
consumption rooms have been reduced by 
acknowledgement at UN and UK government 
level that they can form a legitimate part of local 
responses to drug-related harms. But the Scottish 
Lord Advocate’s recent advice shows that a 
clearer legal framework will need to be provided. 
In the meanwhile, as this report explains, it is still 
possible for local areas to develop a discretionary 
model that enables the establishment of drug 
consumption rooms in places which have a high 
concentration of injecting drug use. The longer 
we wait to set them up, the more people will die 
preventable deaths.




The ACMD and other bodies have recommended 
that the UK introduces drug consumption rooms 
(DCRs) to reduce drug-related deaths and other 
drug-related harms. Drug consumption rooms 
are professionally supervised healthcare facilities 
where people can consume drugs in safer 
conditions. 
Robust evidence demonstrates that DCRs are 
effective in reducing self-reported risk behaviors 
associated with injection, such as syringe 
sharing, reaching and staying in contact with 
highly marginalised target populations, reducing 
drug-related deaths, increasing uptake of 
detoxification and drug dependence treatment, 
decreasing public injecting and reducing the 
number of syringes discarded in a vicinity. 
The evidence does not suggest that a DCR 
increases drug use, frequency of injecting, drug 
dealing, drug trafficking or drug-related crime 
in the surrounding environment. A DCR offers 
numerous benefits to the community and to 
people who use drugs.
The UK is currently experiencing record numbers 
of drug-related deaths, particularly among 
people who use opioids and who are not in drug 
treatment. These deaths could escalate even 
further following the emergence of fentanyl, a 
highly potent opioid which has been linked to 
at least 60 deaths since December 2016. Call-
outs for the removal of drug-related litter are also 
rising with Leeds, Cardiff, Doncaster, Belfast, 
Liverpool and Sheffield seeing an increase in the 
last five years. 
Existing policies are failing to meet the needs 
of the UK’s communities and society’s most 
vulnerable people. The evidence indicates that 
DCRs could address this gap in provision, but 
that there are a number of issues affecting 
feasibility. This report examines these issues.
The answers lie with the innovations occurring in 
Glasgow and Dublin. The Glasgow Health and 
Social Care Partnership is currently identifying 
a site for a DCR, and the Irish Health Service 
Executive is undergoing a tendering process for 
a service in Dublin city centre. 
The first hurdle would be making the case that 
the facility would have sufficient impact. People 
will not travel to use a DCR and thus qualitative 
and quantitative data collection should be used 
to identify a location for the service where there 
is a concentrated drug-using population. A 
business case should also be guided by other 
needs than just the presence of an open drug 
scene, which the UK may not see to the same 
extent as international comparators. 
Funding is a core concern and financial provision 
should not come solely from treatment budgets, 
which are already under significant strain. 
Alternative funding streams may include: central 
budgets, contingency funding, diversion from 
services targeted towards the population who 
are likely to use the DCR such as  homeless 
addiction services, or diversion from services 
which would see savings as a consequence of 
the DCR being established. It is appropriate 
that funding is allocated to a DCR as existing 
services are failing to engage marginalised 
groups and failing to address drug-related litter 
and public injecting, which is a significant burden 
in some communities. 
Residents may have concerns that a DCR will 
create more drug-related disorder, though 
evidence points to the contrary. The community 
should be continually engaged in the proposal 
and clear communication channels provided 
with the local authority. As evidenced elsewhere, 
levels of community support are likely to increase 
after the facility is established. To avoid media 
coverage derailing attempts to establish a DCR, 
stakeholders are advised to seek out media 
opportunities to promote the proposal, though 
the expression of formal interest by the locality 
should be accompanied by a bedrock of local 
stakeholder support. 
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To encourage support from politicians, the 
proposal should be championed by their peers 
and framed as a humanitarian, evidence-based 
intervention, rather than as a wider call for drug 
reform. It is also advantageous for structures to 
be in place that ensure politicians are involved 
and consulted throughout the planning and 
development process and prior to key political 
decisions. DCR acceptability also depends on 
how consistent it is with the recovery agenda. 
Although the primary remit is to reduce harm, 
DCRs are a recovery-orientated service as 
they improve engagement with treatments for 
addiction, offer care and support, and address 
adverse life circumstances. 
The legality of DCRs was cited as one of the 
most significant feasibility hurdles, as there are 
persisting legal barriers that would challenge 
its operation. A DCR could operate through 
a discretionary model, pursuant to guidance 
given by the police and prosecution service. 
Alternatively, a discretionary model could operate 
without legal guidance from the prosecution 
service and instead rely solely on multi-agency 
support, with local stakeholders signing a 
document regarding the establishment and 
running of the DCR. A legislative route is a longer 
process but offers a more stable and permanent 
legal solution. DCR pilots operating on a 
discretionary legal basis could be used to build 
the case for legislative change. The international 
community does also play a role in determining 
the legality of DCRs. The UN no longer cites 
concerns, and now just asks that DCRs should 
reduce the negative consequences of drug 
abuse and lead to treatment and rehabilitation, 
without condoning or encouraging drug abuse 
and drug trafficking. The international community 
can also be a highly useful source of expertise.  
New policing practices would be required, but 
they are unlikely to be a significant departure 
from existing procedure for policing drug 
services. Forces would benefit from receiving 
clear guidance and legislation and observing 
models of practice in countries with DCRs. 
There may be apprehension over the risks 
involved for DCR operators, but providers can 
turn to existing protocol as most of the risks are 
similar to those they already manage.
It is likely that drug consumption will continue 
outside of service hours, however, to minimise 
the extent to which this occurs, opening hours 
should be balanced against community need and 
local capabilities. 
Stakeholders can learn from innovation in 
Glasgow and Dublin, but can also turn to existing 
practice, realising that the way forward may not 
be a significant departure from well trodden 
paths. By following in the footsteps of Glasgow 
and Dublin, but also turning to what is already 
known, localities will be best placed to replicate 
their progress and success. 
DCRs are now a viable policy option and 















Advisory Council for the Misuse of Drugs
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associated with open drug scenes, and in 
reducing health risks for drug users’ (Home 
Office, 2014, p.5) and the Advisory Council for 
the Misuse of Drugs has recommended that 
DCR provision should be considered by the 
governments of each UK country and by local 
commissioners of drug treatment services (2016).
If the UK accepts that DCRs can bring benefits 
and are very much needed, the question remains: 
how can they feasibly be introduced? Previous 
answers have been hypothetical in nature or have 
had to rely solely on international experience 
(JRF, 2006;  Independent Drugs Commission for 
Brighton and Hove, 2013), but there is now the 
opportunity to turn to Glasgow and Dublin. This 
report considers how concerns relating to the 
impact, funding, acceptability and operation of 
DCRs can be alleviated by offering case study-
based, practical advice from stakeholders in local 
areas ‘close to home’.  
To find out what current concerns and barriers 
could prevent the establishment of DCRs, 
Volteface interviewed 15 people in England and 
Wales who have advocated for DCRs, attempted 
to establish them or raised concerns surrounding 
their provision 3. Interviewee contributions 
were collated and taken to 10 stakeholders in 
Glasgow and Dublin who have been named as 
playing a role in progressing the establishment  
of a DCR (see Appendix 6.1 for further detail  
on methodology). 
Their contributions have been used to make the 
case that current concerns and barriers can be 
overcome and that drug consumption rooms are 
feasible in a UK context. 
Chapter 1 
Introduction
For the first time in the UK and Ireland, the 
establishment of a drug consumption room is in 
progress. A drug consumption room 1 (DCR) is 
a professionally supervised healthcare facility 
where people can consume drugs in safer 
conditions. Additional services include sterile 
injecting equipment, counselling services before, 
during and after drug consumption, emergency 
care in the event of an overdose, primary 
medical care, and a referral to appropriate social 
healthcare and addiction treatment services 
(EMCDDA, 2017a). The Glasgow Health and 
Social Care Partnership is currently identifying 
a site for a DCR, and the Irish Health Service 
Executive is undergoing a tendering process for 
a service in Dublin city centre. These innovations 
offer an insight into how the UK can move 
forward with DCRs. We are currently lagging 
behind many other countries, which have at 
least 96 facilities in operation 2. The case has 
already been well made, multiple times, that 
DCRs would be a worthwhile addition to our 
health and social care offer (Select Committee 
on Home Affairs, 2002; JRF, 2006; Independent 
Drugs Commission for Brighton and Hove, 
2013; ACMD, 2016; CGL, 2017; see Appendix 
6.4). We must now turn to our counterpart 
stakeholders in local areas ‘close to home’ to find 
out how we can act on what we already know. 
We know opioid-related deaths among older, 
marginalised users are rising alarmingly. 
These deaths could rise even further with 
the emergence of fentanyl and other related 
analogues in the UK drug supply. We also 
know that there is robust evidence that DCRs 
are efficacious in engaging and maintaining 
contact with highly marginalised target 
populations, reducing drug-related deaths, 
risky injecting practices, drug-related litter and 
public injecting, and do not lead to increases in 
drug use, frequency of injecting, drug dealing, 
drug trafficking or drug-related crime in the 
surrounding environment. The Home Office 
has acknowledged that there is ‘evidence for 
the effectiveness of drug consumption rooms 
in addressing the problems of public nuisance 
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IF THE UK ACCEPTS THAT DRUG 
CONSUMPTION ROOMS CAN BRING 
BENEFITS AND ARE VERY MUCH 
NEEDED, THE QUESTION REMAINS:  
 
HOW CAN THEY FEASIBLY BE 
INTRODUCED?
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Recent reviews of the evidence base 
conclude that DCRs can be efficacious in 
(Potier, Laprévote, Dubois-Arber, Cottencin 
and Rolland, 2014; EMCDDA, 2017a):
–  Reducing drug-related deaths at a city 
level, where coverage is adequate
–  Reducing self-reported injection risk 
behaviors, such as syringe sharing
–  Promoting safer injecting conditions
–  Reaching and staying in contact with 
highly marginalised target populations
–  Increasing uptake of detoxification and 
drug dependence treatment, including 
opioid substitution 
–  Enhancing access to primary healthcare
–  Decreasing public injecting
–  Reducing the number of syringes discarded  
in the vicinity
The  evidence does not suggest that a DCR:
–  Increases drug use or frequency of 
injecting in the surrounding environment 
–  Increases drug dealing, drug trafficking 




The benefits of DCRs have not always been apparent as the evaluations of the original 
facilities located in Europe were not widely published in international literature (EMCDDA, 
2017a). However, when DCRs were established in Sydney in 2001 and Vancouver in 2003, 
multiple university standard evaluation studies were undertaken which strengthened the 
existing evidence base. In 2006, an Independent Working Group on DCRs, convened by 
the Joseph Rowntree Foundation, concluded from the evidence base that DCRs ‘offer a 
unique and promising way to work with the most problematic users, in order to reduce the 
risk of overdose, improve their health and lessen the damage and costs to society’ (2006, 
p.108). Since then, numerous evaluations have been published and the evidence base 
has been further strengthened. In 2014, the Home Office recognised the evidence for the 
effectiveness of DCRs in reducing drug-related harm among local communities and people 
who use drugs (PWUD) (Home Office, 2014).
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Chapter 3  
Need
Calls for DCRs have arisen from concerns about 
persisting and increasing needs among people 
who use drugs (PWUD) (Select Committee on 
Home Affairs, 2002; JRF, 2006; Independent 
Drugs Commission for Brighton and Hove, 2013; 
ACMD, 2016). These calls have become more 
urgent as a result of increases in drug-related 
deaths right across the UK (Office for National 
Statistics, 2017; National Records of Scotland, 
2017; Northern Ireland Statistics and Research 
Agency, 2015). In England and Wales, they are 
now at their highest level since comparable 
records began in 1993 (see Figure 1) (Office for 
National Statistics, 2017) and account for 31% of 
European drug-related deaths (EMCDDA, 2017c).
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Figure 1.   Age-standardised mortality rates for 
deathes related to drug misuse, by sex, 
deaths registered in 1993 to 2016. 












The ACMD’s examination of rising opioid-related 
deaths concluded that the most significant 
contributing factor has been the premature ageing 
of people who have been using heroin since the 
1980s and 1990s, alongside increasingly complex 
health needs resulting from long-term conditions 
and polysubstance use. This trend takes place 
within a context of existing social care needs 
and continuing multiple risk behaviours. Another 
identified cause was the rise in availability of street 
heroin after a ‘heroin drought’ in 2010-2012, 
during which the purity of heroin fell and street 
prices increased.  Changes to drug treatment and 
commissioning practices have also been named 
as contributing factors. These include: sub-
optimal dosing of opioid substitution treatment 
putting PWUD at greater risk of overdose, and 
frequent recommissioning of services diminishing 
their ability to retain people in treatment (ACMD, 
2016). Retention in treatment is a protective factor 
against drug-related death, where treatment 
comprises of optimal opioid substitution treatment 
(OST) and psychosocial interventions (White et al, 
2015). It should be noted though that the majority 
of drug-related deaths occur among people who 
have had no contact with treatment services 
(Public Health England, 2016). The ACMD has 
also cited rising socioeconomic deprivation and a 
lack of access to mainstream mental and physical 
health services as possible contributors (2016). A 
combination of rising health needs and inadequate 
service provision has left a cohort of people at 
greater risk of drug-related death. The ACMD has 
recommended that DCRs should be considered 
as an intervention for drug-related deaths and 
other drug-related harms (2016, p.40).
There are concerns that drug-related deaths 
could further escalate with the emerging 
prevalence of fentanyl and related analogues 
(fentanyls) in the UK drug market. Fentanyls are 
synthetic opioids that come from the same family 
as heroin, but are far more potent on a weight 
for weight basis (O’Connor, 2017). Fentanyl is 
approximately 50 times more potent than heroin, 
with some related analogues being significantly 
stronger (NCA, 2017a).
In August 2017, the National Crime Agency 
warned that post-mortem toxicology results had 
indicated that 60 drug-related deaths in the 
UK were known to be linked to fentanyls since 
December 2016 (NCA, 2017a). Although it is 
currently unclear why fentanyls have emerged 
in the UK drug market, they pose the risk of 
escalating an existing crisis in opioid-related 
deaths and DCRs have been recommended as 
an intervention which could control potential 
outbreaks (CGL, 2017).
A Freedom of Information Request has also 
shown that call-outs to local authorities for the 
removal of drug-related litter is rising in some  
UK cities.  
 
Drug-related litter adversely affects public 
amenity and could transmit infectious diseases, 
such as HIV and Hepatitis C, through 
needlestick injuries (See Figure 2) (Leeds City 
Council, 2017; City of Cardiff Council, 2017; 
Doncaster Council, 2017; Belfast City Council, 
2017 Liverpool City Council, 2017; Sheffield  
City Council, 2017) 4 
National and local monitoring indicates  
that existing policies are failing to curb drug-
related harms, which could be addressed 
through DCRs.   
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Call-Outs for the Removal of Drug-Related Litter
Figure 2.   Call outs for the removal of drug-related litter
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Chapter 4 
Policy Developments in Glasgow and Dublin
Innovative policy responses have been taken 
forward in Glasgow and Dublin to respond to 
persisting and increasing drug-related harms. 
Both cities have made significant progress in 
establishing a DCR, with Glasgow City Health 
and Social Care Partnership currently identifying 
a site and the Irish Health Service Executive 
undergoing a tendering process for the service 
since the passing of the Misuse of Drugs 
(Supervised Injecting Facilities) Bill.
In 2015, Glasgow saw a significant HIV outbreak 
among people who inject drugs, with 47 new 
diagnoses compared to a previous annual average 
of 10 (see Figure 3) (Tweed and Rodgers, 2015). 
Figure 3.   New HIV diagnoses among people  
who inject drugs in NHSGGC










In response to this outbreak and accumulating 
evidence of poor health and injection-related 
harm among people who inject drugs in Glasgow 
city centre, a local needs assessment was 
commissioned by NHS Greater Glasgow and 
Clyde (NHSGGC), which aimed to investigate 
how the city could better meet the needs of  
this population (Tweed and Rodgers, 2015).  
A number of priorities for health service provision 
were identified, with public injecting named as a 
risk factor for:
–  Bloodborne viruses
–  Overdose and drug-related death
–  Other injecting-related complications, such as 
abscesses, wounds, and deep vein thrombosis
Seven recommendations came out of the 
needs assessment, the most novel being that 
the city should pilot Heroin Assisted Treatment 
(HAT) and a DCR. A short-life working 
group was convened to address NHSGCC’s 
recommendations and proposed that a business 
case be made for a co-located DCR and HAT 
service. A co-located service was the preferred 
model as it was considered the most likely 
to  improve the health of the target population, 
benefit communities and businesses currently 
adversely affected by public injecting, maximise 
the potential for service efficiencies, and take 
forward the recommendations of the health 
needs assessment (Millar, 2016a).
HAT involves prescribing medical grade heroin, 
administered under strict controls, to people who 
have failed to benefit from OST. Randomised 
control trials have tested HAT against oral 
methadone and injectable methadone, 
concluding that treatment with supervised 
injectable heroin leads to significantly lower use 
of street heroin than does supervised injectable 
methadone or oral methadone (Strang et al, 
2010). Glasgow interviewees explained that a 
DCR will run in tandem to HAT as not all persons 
will be  ready to accept HAT. The service places 
higher demands on the person as, to be eligible, 
there must be evidence of previous unsuccessful 
treatment episodes and the person must attend 
the service, initially, three times a day and during 
specified periods that the service is open. 
HAT is also a highly cost-effective treatment  
(Strang et al, 2010) but is costly to operate,  
and potentially not affordable for the service  
to be offered widely. 
The working group has since provided a further 
update on the development of this co-located 
service, with all recommendations  approved 
by the Integrated Joint Board (Millar, 2016; 
2017a; 2017b; 2017c).  The  group is currently 
identifying a site (Millar, 2017b) and is working 
with the Scottish Government to ensure that the 
appropriate legal context is in place to support 
the implementation and sustainability of the DCR 
(see section 4.3).   
Ireland has experienced high drug-related harms 
in comparison to other EU countries, but these 
harms have been concentrated in Dublin, which 
has disproportionately high levels of opioid use, 
drug-related deaths (Long and Lyons, 2010; 
EMCDDA and Health Research Board, 2017)  
and HIV rates. Ireland has seen a significant rise  
in HIV, with increases of 81% in 2015 among 
people who inject drugs, with the majority of the 
new diagnoses occurring in Dublin (HPSC, 2016)
Public injecting is also highly prevalent in 
Dublin city centre. In 2013, Dublin city centre 
treatment provider Merchants Quay identified 
that 14% of people who use its needle and 
syringe programmes generally injected in 
public places, which can be extrapolated to 
375 people (Jennings, 2013). A drug mapping 
project undertaken by the Ana Liffey Drug Project 
identified 1,750 individual pieces of drug- related 
litter in the North Inner City area over a two-week 
period in 2016 (ALDP, 2017).
14
All of these drug-related harms have taken place 
within the context of rising homelessness across 
Ireland, which, again, has been concentrated in 
Dublin (Department of Housing, Planning and Local 
Government, 2017). 
In response to these persisting and increasing 
drug-related harms, and the publication of new 
international evidence on DCRs, Dublin-based drug 
and alcohol treatment provider, the Ana Liffey Drug 
Project, launched a strategic planning process 
which aspired to:
–  ‘Advocate secure stakeholder support and plan 
for the establishment of a Medically Supervised 
Injecting Centre (MSIC) by September 2013. 
–  Subject to above and necessary legislative 
amendments, pilot a MSIC in Dublin offering a 
practical and safer alternative to public injecting 
by December 2014’ (ALDP, 2012)
As a consequence of championing by the Ana 
Liffey, Senator Aodhán Ó Ríordáin and Minister 
for State Catherine Byrne, the Misuse of Drugs 
(Supervised Injecting Facilities) Act 2017 was 
enacted by the Dáil Éireannin in May 2017, which 
provides ‘for the establishment, licensing, operation 
and regulations of supervised injecting facilities  
for the purposes of reducing harm to people who 
inject drugs’ (House of the Oireachtas, 2017). 
The innovations taking place in local areas ‘close 
to home’ offer counterparts new opportunities to 
consider how a drug consumption room could  
be introduced in a UK context. 
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5. 1. Impact 
5.1.1. Location 
A DCR should be a local intervention that responds 
to the needs of the local drug-using population. 
However, this does mean that a DCR has to be 
accessible to that local drug-using population, 
as people typically use their drugs soon after 
purchasing them and thus will not travel far to use 
a DCR (Tweed and Rodgers, 2015; Millar, 2016). A 
challenge faced by one locality was that it could not 
make the case that its drug-using population was 
sufficiently concentrated enough for the facility to 
offer a return in investment.  
In Glasgow, NHSGGC firstly identified that there 
was a cohort of people who publically injected 
in Glasgow city centre who  would benefit from 
a DCR established in that area. These estimates 
came from applying published prevalence estimates 
of public injecting (Hunt, 2006) to recent data from 
local needle and syringe programmes. The data 
concluded that there were between 400 and 500 
individuals who may be injecting in public places 
in the city centre on a regular basis (Tweed and 
Rodgers, 2015, p.28). 
The Health and Social Care Partnership then used 
a combination of quantitative and qualitative data 
collection methods to evidence that a DCR would 
be used by the targeted population, if it was placed 
in the city centre. Questionnaires were distributed 
to needle and syringe programmes in Glasgow city 
centre and adjoining areas. Among other questions, 
the questionnaire asked if the respondents would 
use a DCR in Glasgow city centre and 79% 
reported they would.  
Within the questionnaire, respondents were asked 
if they were happy to be contacted again and this 
sample were invited to a DCR focus group hosted 
by the Scottish Drug Forum (SDF). To increase the 
number of participants on the day, SDF volunteers 
ventured into Glasgow city centre and asked 
people who were on the streets to come in and 
give their views. A £20 voucher was provided to 
those who gave up their time to participate, and 
lunch, tea and coffee were offered on the day. 
Chapter 5 
Feasability
Unanimously, the focus group agreed that a DCR 
should be provided. Though attendees said they 
would not travel to use the service, the people 
invited to the focus group were sampled from 
Glasgow city centre and adjoining areas, which will 
be the proposed location of the DCR (Millar, 2016). 
By consistently sampling from the drug-using 
population in Glasgow city centre for all 
data collection, the Health and Social Care 
Partnership was able to make the case that a 
DCR would be sufficiently used if it was located 
in Glasgow city centre. 
In Dublin, the Health Service Executive identified a 
location that would ensure the site was sufficiently 
used by surveying known street injectors, mapping 
drug-related deaths, ambulance service and fire 
brigade callouts,  and identifying drug-related litter 
hotspots. Its working group concluded that Dublin 
city centre would see the facility offering significant 
return on investment (Health Business Services, 
2017). 
Recommendation:  
PWUD are unlikely to travel to use a DCR and 
the locality would need to demonstrate that there 
is a concentrated drug-using population. The use 
of quantitative and qualitative methods, which 
collect data from  
a range of stakeholders and only sample within 
the targeted local areas, can build the case 
that the facility will be sufficiently used in the 
identified location. 
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“YOU COULDN'T JUST WALK UP 
BUCHANAN STREET AND SEE 
INJECTING EQUIPMENT”
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5.1.2. Visibility of Drug Use 
‘The precarious situation in Germany’s largest open 
drug scene – the Taunusanlage in Frankfurt am 
Main – had resulted in almost 200 deaths in public 
spaces at that time and increasingly concerned the 
citizens, politicians and city government’  
(AK Konsumraum, 2011) 
There are multiple community needs that a DCR 
can address, but responding to open drug scenes 
has been a key driving force for their establishment 
in other countries. Open drug scenes affect the 
wider community rather than just PWUD, who have 
historically had little opportunity to impact public 
policy. Although a study has evidenced that the UK 
experiences high rates of public injecting (Hunt, 
2006), interviewees described an incidence where 
a proposal for a DCR struggled to gain traction as 
the public drug consumption that was occurring in 
the area was not as evident as it had been in areas 
such as Frankfurt or Vancouver. One would need to 
know where to look to find evidence of it. 
Glasgow interviewees acknowledged that, although 
there are possibly hundreds of people using drugs 
in public places in the city centre, there is not an 
obvious open drug scene, with drug use more 
hidden than that experienced by its international 
counterparts.  
‘You couldn’t just walk up Buchanan Street and 
see injecting equipment, but if you walked up one 
of the alleyways not far from there then you very 
well might... if you’re not going out to look for it 
then you probably won’t see it. You certainly see 
a lot of homeless people, people begging, people 
intoxicated but to actually visibly see injecting 
equipment and people injecting in public, like has 
been seen in Vancouver, it just isn’t the case. I 
guess for some people they have no idea that the 
problem actually exists, it’s a very hidden thing’  
 
Kirsten Horsburgh,  
National Naloxone Coordinator,  
Scottish Drug Forum
The Ana Liffey agreed that a similar situation exists 
in Dublin. 
‘If you were to walk around Dublin city now 
you may not see any drug-related litter on 
the streets, however, if you were to turn and 
go 30 feet down an alleyway, you might or 
might not find a syringe, but you will find 
other types of drug-related litter… 
I’ve shown people what to look for and it 
has been said to me it’s like one of those 
magic pictures where the image gradually 
emerges and the image that appears  
is shocking… ’ 
 
Tony Duffin, CEO,  
Ana Liffey Drug Project
However, multiple drug-related harms can persist 
without having a highly visible presence and need 
was also evaluated by a wider criteria than just the 
presence of an open drug scene. Moreover, what 
was highlighted by both localities was that the 
decision to progress the establishment of a DCR 
had been grounded in a local needs assessment 
rather than international comparisons. 
Recommendation: The presence of obvious, open 
drug scenes has been a key driving force for their 
establishment in other countries which the UK, 
arguably, does not experience to the same extent. 
However, the case can be made that needs persist 
even if a drug-using population is relatively hidden. 
Moreover, the decision to establish a DCR should 
be guided by a local needs assessment, rather 
than international comparisons of need.
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5. 2. Funding 
5.2.1. Funding Streams 
Recent budgetary cuts to drug and alcohol 
treatment are of significant concern. In December 
2016, the Government announced that local 
authorities will receive £84 million less for public 
health in 2017/18, which has followed a £77 
million reduction in 2016/17, and a £200 million 
cut in 2015/16. On average, local areas have 
seen drug and alcohol treatment cut by 30%, 
though some areas have seen cuts of up to 50% 
(Drummond, 2017) . There is limited additional 
resource in drug and alcohol treatment and 
some interviewees were apprehensive that the 
opportunity cost of investing in a  DCR would 
result in further disinvestment from treatment 
provision, putting further lives at risk. The ACMD 
has advised that its primary recommendation 
for reducing drug-related deaths is for the 
Government to, at the very least, maintain 
investment in OST of optimal dosage and  
duration (2016, p.3). 
The Glasgow Health and Social Care Partnership 
has acknowledged that treatment budgets are 
under strain and, thus, the DCR has not been 
funded by a diversion of existing mainstream 
treatment budgets. Interveiwees commented 
that, instead, resources are being realigned 
from services targeted towards the population 
who are likely to use the DCR, for example, 
homeless addiction services. It was emphasised 
that resource will be diverted from these existing 
services without diminishing core provisions. 
New money is also being allocated to the service 
through a contingency fund, which will finance 
the pilot service for three years (Millar, 2017b). 
Contingency funding was deemed to be an 
appropriate funding stream due to the emergence 
of  urgent issues, notably drug- related deaths and 
new diagnoses of HIV. 
‘Most of the funding currently identified is from 
that contingency fund, the other is the redirection 
of current resource, but resources that are already 
at the moment aligned to this population. So its 
supplanting the current resource with more, in 
order to deliver a bigger agenda for  
that population’  
 
Dr Saket Priyadarshi,  
Glasgow Associate Medical Director  
at Addiction Services NHSGGC
Funding for the Dublin DCR was identified 
through Ireland’s Department of Health central 
budget. Interviewees commented that there 
was little difficulty in raising additional funds for 
the DCR as the cost was not substantial when 
taken out of a national budget. No diversion from 
existing treatment budgets occurred. 
Recommendation: Treatment budgets are 
under  significant strain and further significant 
diversion would have a detrimental impact 
on provision. In Glasgow and Dublin, there 
is no evidence of DCRs being funded from 
a diversion of treatment budgets. Alternative 
funding streams can include centralised funding, 
contingency funding or resources realigned 
from existing services targeted towards the 
population who are likely to use the DCR, 
without diminishing core provisions. 
 
5.2.2. Cross Divisional Savings  
A DCR  can lead to substantial savings across 
different departments by, for example, reducing 
drug-related disorder, improving public amenity 
and reducing the burden on emergency health 
services. Studies have attempted to estimate the 
societal cost savings, most commonly through 
predicted reductions in HIV (Andreson and Boyd, 
2010; Bayoumi and Zaric, 2008; Pinkerton, 2010). 
One interviewee raised the concern that, in some 
local areas, budgets do not account for these 
cross divisional savings. Other departments may 
feel the benefits of the DCR but not make any 
financial contribution to its operation. 
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The Health and Social Care Partnership  
has recognised the cross divisional savings  
a DCR can offer as, during the course of the  
three-year pilot, NHSGGC will evaluate where  
the service provides benefits and savings to  
other parts of the health and social care and  
wider system, which subsequent funding 
packages will reflect. Thus, the city is taking  
an invest-to-save approach, with an evaluation 
that includes a cost benefit analysis.
‘If this evaluation demonstrates the  
[DCR] does improve the health of  
service users and reduces pressures  
on associated services, there would  
be a case to redirect resources from  
those services to fully fund the  
service from year four’  
 
Dr Saket Priyadarshi, Associate Medical  
Director, Addiction Services at NHS  
Greater Glasgow and Clyde
For Dublin, the Department of Health will  
continue to fund the facility if the evaluation  
merits the continuation of the project. As the 
funding comes from a national health budget, 
different divisions within the Department of  
Health will feel the costs and benefits. 
Recommendation: DCR funding packages 
can reflect cross divisional savings by coming 
from a centralised, cross departmental budget. 
Alternatively, funding packages can be informed 
by evaluations which indicate where savings  
are felt once the service is established.
5.2.3. Cost-Effectiveness  
NHSGGC has estimated that the operating costs 
for a DCR will amount to £1,000,000, a figure 
which will be confirmed once the site is identified. 
The Ana Liffey has estimated a similar operating 
cost for the Dublin DCR. Both service designs 
have been modelled on the Sydney Medically 
Supervised Injecting Centre. 
International evidence demonstrates that DCRs 
are a highly cost-effective service which can result 
in substantial savings (Bayoumi and Zaric, 2008; 
Pinkerton, 2010; Salmon, Van Deek, Amin, Kaldor 
and Maher, 2010). 
The Glasgow HSCP have calculated that A+E  
and acute admission costs for the estimated 
350 who inject drugs in the Glasgow city centre, 
amounts to 1.7 million. The average medication-
only cost per patient receiving HIV treatment is 
currently £6,403 per annum; this figure does 
not include the costs of clinic appointments, 
laboratory monitoring, or treatment for any 
complications arising. In February 2017, there 
were 78 confirmed cases in the outbreak of 
HIV from the start of 2015 and the outbreak is 
ongoing. If these costs were realised for the 
individuals affected by the outbreak, then this 
would equate to £28 million lifetime costs; 
including £500K per annum medication costs 
(Millar, 2017a). The evidence indicates that 
investment in a drug consumption room could 
reduce spending in these areas.
However, one interviewee raised the concern 
that it would be challenging to allocate such a 
significant amount of resource to a relatively small 
cohort of people, especially with the availability of 
more affordable interventions such as Naloxone, 
needle and syringe programmes and OST. 
The 2015 Glasgow local needs assessment did 
conclude that ‘the quality of service provision for 
people who inject drugs in Glasgow compares 
well to other areas of the UK and to international 
standards’ (Tweed and Rodgers, 2015, p.19).  
The needs assessment also made 
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recommendations to further improve and invest 
in this provision, such as increasing the opening 
hours of needle and syringe programmes. 
However, the needs assessment identified that 
PWUD drugs in Glasgow city centre had, for 
years, consistently been at the epicentre of 
outbreaks and other harms, despite investment 
in prescribing services, needle and syringe 
programmes, and during times of high retention in 
drug and alcohol treatment. As ‘previous attempts 
to address the problem of public injecting in 
Glasgow have not curtailed the harms experienced 
by this population’, NHSGGC recommended that 
new and innovative approaches were required to 
meet their needs (Tweed and Rodgers, 2015, p.6)
‘It obviously wasn’t working… I think that’s why 
changes need to be happening because people 
are still dying… people don’t even know how to 
inject properly and they’re causing themselves 
damage, people are losing limbs and contracting 
bloodborne viruses, and there needs to be 
something that people can access, because a 
lot of the people who are using in the city centre, 
they’ve been through services one million and one 
times and it’s never worked and there’s a good 
reason that it’s never worked, I think it’s just about 
trying something else and there’s evidence there 
that it is successful’ 
Claire Muirhead, Chair of South Community 
Recovery Network and Lived Experience 
By attracting marginalised groups, a DCR can 
deliver a ‘Making Every Contact Count’ approach, 
where services can utilise day-to-day interactions 
to encourage behaviour change that has a positive 
effect on individual health and wellbeing (Health 
Education England, 2017).
The Glasgow needs assessment also indicated 
that no existing initiatives have been able to 
resolve long- standing local community concerns 
surrounding public injecting and drug-related 
litter (Tweed and Rodgers, 2015). A Freedom 
of Information request  revealed that in 2016/17, 
Glasgow saw a 68% increase in call-outs to the 
local authority for the removal of drug-related  
litter (Glasgow City Council, 2017). 
‘I’ve examined the issue of the needles being 
dispensed and not being returned. From that 
experience, I fully understand the public health 
reasons for issuing fresh needles in order to 
reduce the transmission of bloodborne diseases 
like HIV.  Throughout this period, my concern 
has been focused on the risks passed on to the 
population at large if needles are just going to be 
discarded in public places. There doesn’t seem 
to be any way around the problem of needle 
discard, other than looking at a consumption 
room and taking the drugs taking away from back 
lanes, streets, waste ground, and into a suitably 
equipped and monitored premises…[Currently] 
the cost of needle discard falls to other people, it 
falls to housing associations, it falls to the council, 
it falls to emergency services, it falls to all kinds  
of other groups and sometimes in ways that are 
not calculated.’  
 
Alison Thewliss,  
MP for Glasgow Central
Thus, the establishment of a DCR is not just  
about investing in a relatively small cohort 
of people, it is about investing in the wider 
community by reducing drug-related litter  
and incidences of public drug injecting. 
Dublin interviewees commented that questions 
regarding cost and cost effectiveness had not 
played a central role in Ireland.  A criticism the 
proposal did face was that PWUD would have 
their needs better met through investment in 
treatment. However, investment in treatment  
would have had limited impact as the problem of 
public injecting in Dublin city centre had persisted 
for more than 30 years and existing services were 
not addressing it. Treatment can meet the needs 
of some people, but there are others who are not 
interested or ready to enter treatment and a DCR 
can fill this gap in provision.
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Recommendation: A locality will have to justify 
why resources should be allocated to a relatively 
small cohort of people, especially with the 
availability of more affordable interventions. The 
case can be made that a DCR can bring benefits 
not provided by other interventions, as it can 
successfully build relationships with hard to reach 
groups who are not engaging in current provision.  
Existing interventions are also failing to address 
drug-related litter and public injecting, which is a 
significant burden in some communities. Thus, the 
establishment of a  DCR is not just about investing 
in a relatively small cohort of people, it is about 
investing in the wider community by reducing 
drug-related litter and incidences of public  
drug injecting.
5.3. Acceptability 
5.3.1. Community Engagement 
Residents living in ‘hotspots’ of public drug 
consumption are likely to have concerns that a 
DCR will create more drug-related disorder and 
may object to proposed site locations, though 
evidence indicates that DCRs reduce the impact 
of drugs on communities. Most interviewees felt 
that there would be significant challenges in 
engaging the local community as the proposal 
would invoke ‘nimby-ism’ (Not In My BackYard) . 
The Glasgow Health and Social Care Partnership 
is currently identifying a site. Once this is done, a 
community engagement process will take place.  
Dublin is at a more advanced stage, with the 
Health Business Services recently releasing 
an invitation to tender. The tender specification 
includes the recruitment of a Community Liaison 
Worker Officer whose role will be to engage 
local businesses, communities and residents in a 
meaningful manner and set up a system for local 
monitoring. This would involve regular meetings 
with local stakeholders and reporting  back to 
Ireland’s Operational Governance Committee. 
This specification is in accordance with 
EMCDDA guidance that ‘consultation with local 
key actors is essential to minimise community 
resistance’ (2017a, p.5). The invitation to tender 
also advises that local opinion before and after 
the opening of the facility should be recorded 
and reported on (2017). International evidence 
indicates that levels of community support for a 
drug consumption room increase after they are 
established (Thein, Kimber, Maher, Macdonald 
and Kaldor, 2005).  
Recommendation: Despite evidence 
demonstrating that DCRs have a beneficial 
impact on local communities, residents are likely 
to have concerns that a DCR will create more 
drug-related disorder. If a DCR succeeds in 
delivering on its promises, it is likely that levels of 
community support will increase, as evidenced 
elsewhere. Until that time, the community should 
be continually engaged in the proposal and 
clear communication channels with the local 
authority should be provided. The recruitment 
of an individual with a designated position to 
do so  could be an effective way of maximising 
engagement. 
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5.3.2. Media Engagement 
It is likely that a DCR proposal would, initially, be 
perceived as contentious as the authorities would 
be  providing a premises where people can use 
illicit drugs. Most interviewees cited concerns that 
the media reaction to the proposal would entrench 
misconceptions surrounding DCRs and obstruct 
positive public engagement with the facility.  
Yet the response from the media to the Glasgow 
DCR has been overwhelmingly positive so 
far. NHSGGC has explained that this reaction 
was a consequence of the media engagement 
undertaken by its  communications department 
and strong support for the initiative among 
partner agencies, people with lived experience 
and experts at the local level. 
NHSGGC managed the publication of each of 
the Integrated Joint Board updates by working 
closely with the Health and Social Care 
Partnership to create detailed and accurate 
press releases for the media. The press releases 
were first sent to all stakeholders, ensuring that 
they were aware of the most recent service 
developments if contacted by the media. To keep 
the media engaged with the process, newsworthy 
content was included in the press release, as 
well as the key elements of the Integrated Joint 
Board update. NHSGGC also formulated a list 
of FAQs for media outlets to refer to, ensuring 
that information was transparent and easily 
accessible (Health and Social Care  
Partnership, 2016). 
The DCR proposal received mostly favourable 
coverage from media outlets, with The Times 
and The Herald taking positive editorial stances. 
Others chose not to report on the issue. The 
Daily Mail was the only news outlet which was 
strongly critical of DCRs, yet was unable to find 
local stakeholders who were opposed to the 
initiative. NHSGGC commented that solidarity 
at the local level created a strong foundation for 
subsequent engagement with the media. 
Media engagement began at an earlier point  
in Dublin as the process was driven to a greater 
degree by moral and political acceptability. 
The Ana Liffey was advised that DCRs were a 
newsworthy item and that it could create its own 
news stories to move DCRs up the agenda and 
manage perceptions of acceptability.  
The organisation planned for five interactions  
per week on DCRs on online media and also 
sought out opportunities for TV, radio and 
opinion pieces. 
‘Radio has been a good communication 
platform for these purposes; listeners 
want to hear the human story and radio 
has given people who are affected a voice 
and a level of anonymity that has given 
them some comfort. Listeners can hear  
the person’s story, hear their heartache 
and the tragedy of the story.’  
 
Tony Duffin, CEO,  
Ana Liffey Drug Project
The charity  strongly advised  that advocates 
should  engage with the media as not doing 
so would leave a void that could be filled with 
detraction and misinformation. 
Recommendation: Media engagement is 
essential for facilitating community acceptance 
of DCRs and advocates are advised to 
seek out media opportunities to promote 
DCRs. Radio interviews are cited as a highly 
persuasive communication tool, with the voice 
of lived experience  and families  powerful 
in early work and for softening the way for 
informed discussion. Local commentators and 
stakeholders should be engaged in the proposal 
prior to the media release to ensure that the 
locality presents a united front. Press releases 
should be detailed, newsworthy and shared 
and drafted with all partners. Any additional 
information and FAQs should be in an easily 
accessible format.
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5.3.3. Political Support 
Drug policy is an area which politicians can 
be reluctant to speak about, with the UK Drug 
Policy Commission concluding in its final report 
that ‘there is little political space for informed 
debate about policy options’ (UKDPC, 2012, 
p. 134). Interviewees commented that, from 
their experiences, politicians can be reluctant 
to publically declare their support for alternative 
drug policies. 
However, the opposite has occurred in Glasgow 
and Dublin. When Glasgow’s intention to 
pilot a DCR was announced in October 2016, 
there were no public objections from Scottish 
politicians. Glasgow interviewees advised that 
politicians needed to feel safe in supporting a 
DCR, which can be encouraged by their peers 
publicly supporting the proposal.
‘We decided we were going to put a line 
out from me in the office to say that I 
was supportive of the proposal, and why. 
In speaking to them [councillors] they 
were quite pleased and surprised that 
I had done that. The councillors on the 
Integrated Joint Board seemed concerned 
that this proposal was going to be a 
difficult thing to sell to the public… I’m 
quite glad that there has been cross-
party holding of the line on it, because all 
it takes is for a couple of people to start 
objecting and throwing their hands up for 
this important intervention to falter.’  
 
Alison Thewliss,  
MP for Glasgow Central
Efforts were also made to depoliticise the 
proposal by framing it as an evidence-based 
intervention that  was responding to rising and 
changing need, rather than being driven by a 
drug reform agenda.
‘Across the world when we look at this, 
it’s quite often high profile politicians 
and public leaders who have taken this 
through. In the UK, there doesn’t seem 
to be an appetite. Alison Thewliss has 
been very helpful and supportive but we 
don’t have anybody in high office, or a 
Secretary of State or a Prime Minister or 
a high profile cabinet member taking this 
through. Actually it’s been the bravery 
of very senior officers in our Health and 
Social Care Partnership who have taken 
this through, given it the authority for it to 
be taken as far as it has here. And a very 
systematic step by step explanation of the 
evidence base and the business case to 
the Integrated Joint Board, so that we can 
make the case with as little emotion as 
possible and just saying this is the right 
thing to do for the city centre’  
 
Dr Saket Priyadarshi,  
Associate Medical Director, NHSGGC
The structure of the Integrated Joint Board was 
able to mitigate any automatic political objections 
as half of the board was comprised of councillors 
who were engaged early in the process, 
presented with the evidence and jointly tied  
into decision-making.
The position of the Scottish Government has 
been accommodating to local decision-making 
in Glasgow, with Public Health Minister Aileen 
Campbell stating in June 2016 (Allen, 2016):
‘The Scottish Government has no plans  
to introduce drug consumption rooms or  
heroin-assisted treatment on a national  
basis. This is a matter for Glasgow City  
Alcohol and Drug Partnership and NHS  
Greater Glasgow and Clyde health board.  
We would encourage the health board to  
ensure it consults with communities before 
making any decisions. We constantly look  
at new developments in drugs policy to  
see how effective they are and we would 
encourage an independent evaluation of  
any such facility.’
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The Scottish Government is  also supporting the 
Glasgow Health and Social Care Partnership 
to ensure that the appropriate legal context 
is in place to support the implementation and 
sustainability of the DCR (see section 5.4). 
Interviewees commented that the Scottish 
Government could be accommodating to 
the policy developments in Glasgow as the 
Government had been fully informed of the 
process, with one of its  representatives sitting 
on the DCR short life working group. 
Similarly to the Scottish Government, the UK 
Home Office has stated that it ‘has no plans to 
introduce drug consumption rooms’. However, 
its statement on DCRs adds that, ‘it is for 
local areas in the UK to consider, with those 
responsible for law enforcement, how best to 
deliver services to meet their local population 
needs’. It can be inferred from this that the Home 
Office has become more accommodating to 
local agency surrounding DCRs, though far less 
explicitly than the Scottish Government.  
A greater public debate has been had in 
Ireland where political champions played a 
more prominent role. Minister of State Aodhán 
Ó Ríordáin and Catherine Byrne were able to 
use their influence to secure safe passage for 
legislation which made it legal for the DCR to be 
piloted. After being approached by the Ana Liffey, 
Senator Aodhán Ó Ríordáin was the first political 
advocate for the facility and framed the proposal 
primarily as a humanitarian response.
‘I was trying to put a group of people at 
the heart of a public policy initiative and 
I think people could see what I was trying 
to achieve. That was the ideology behind 
it, the sole purpose of it... In politics, if you 
put people at the centre of what you’re 
trying to do, and particularly extremely 
vulnerable people, then people accept 
you’re bona fide. It’s not as if it’s politically 
advantageous, it’s not as if it’s a sector 
who are voting or have power, they don’t 
have huge access to mainstream media. 
So when you’re advocating on behalf of... 
that sector who don’t have a voice, then 
I think people will accept you... I would 
like to think that ran through in the things 
we were saying… There didn’t seem to be 
anybody saying it was a bad idea, some 
voices on the extremes, but nobody in 
mainstream advocacy or lobbying.’  
 
Senator Aodhán Ó Ríordáin,  
Dublin Bay North
By the time the DCR legislation was being 
publicly debated in Ireland, interviewees 
observed that media outlets struggled to find 
politicians who were opposed to the idea. 
Recommendation: Politicians are more likely  
to be supportive of drug consumption rooms if 
they are championed by their peers and framed 
as an humanitarian, evidence-based intervention, 
rather than as a wider call for drug reform.  
It is also advantageous for structures to be  
in place which ensure politicians are involved  
and consulted with throughout the planning  
and development process and prior to  
key political decisions. 
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“IF YOU TALK THEM OFF THE  
LEDGE THEN YOU CAN TALK  
TO THEM ABOUT THE ISSUES  
THAT HAVE GOT THEM ON  
THERE IN THE FIRST PLACE.  
BUT YOU HAVE TO STOP THEM 
FROM DYING OR GETTING  
A VERY SERIOUS DISEASE” 
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5.3.4. Recovery Agenda 
A DCR was considered unfeasible in one UK 
location due to criticisms from stakeholders 
that, by providing a premises for an individual to 
use illicit drugs, a DCR was inconsistent with 
the recovery agenda, which has put a greater 
emphasis on supporting individuals to lead a 
drug-free life (HM Government, 2010; 2017).
The Glasgow proposal highlights that the service 
is recovery-orientated as it will be:
–  Engaging a population with complex needs in 
effective addictions treatment and care
–  Promoting recovery-orientated support such as 
peer support and mutual aid  
–  Providing opportunities to address and improve 
adverse life circumstances such as housing, 
welfare rights and wider medical needs. The 
facility will be offering wrap around services on 
the same premises and referral pathways into 
wider support services (Millar, 2017b).  
‘A lot of people who are using in the city 
centre, they’re not engaged in treatment 
services and trying to actually get them 
access to the kind of  services that they’re 
needing, providing a nurse for wound care, 
BBVs and other issues is difficult... I walk 
through the city centre all the time and 
there’s never a day goes by where I don’t 
recognise a couple of people who are 
sitting, begging in the city centre, using 
in the city centre, and all these people 
want is for somebody to actually talk to 
them. You know just go in, friendly face, 
somebody who remembers their name’  
 
Claire Muirhead, Chair of South Community 
Recovery Network and Lived Experience 
The Dublin DCR has similar recovery-orientated 
provisions in place by offering medical 
interventions, crisis interventions, counselling 
interventions (if requested) and referrals into 
social services, housing and treatment. It is also 
expected that the service provider should offer 
at least a brief intervention on each attendance 
(Health Business Services, 2017). 
However, Dublin interviewees advised that the 
success of a DCR should be judged on its 
primary purpose, improving health outcomes 
among PWUD.
‘If someone’s on the edge of a building 
and they’re about to  jump off, that person 
may have housing issues, may have 
addiction issues, may have mental health 
issues, may have a whole bunch of issues, 
but your fundamental job is to stop them 
jumping off the ledge. Do everything you 
possibly can and if you talk them off the 
ledge then you can talk to them about 
the issues that have got them on there 
in the first place. But you have to stop 
them from dying or getting a very serious 
disease and that’s what the SIF is. So I’m 
not overplaying it, you have people all over 
who use these centres for years… but they 
don’t get diseases and they don’t overdose 
and die, in a very lonely, pretty depressing 
environment, and that’s all it’s designed  
to do’  
 
Senator Aodhán Ó Ríordáin,  
Dublin Bay North
Recommendation: The recovery agenda, 
which has come to prominence in UK drug 
addiction provision, places a greater emphasis 
on supporting individuals to lead a drug-free life. 
DCRs are a recovery- orientated service as they 
improve engagement with addictions treatments 
and care, offer recovery- orientated support and 
address adverse life circumstances. However,  




5.4.1. Legality   
The legality of DCRs was cited as one of the 
most significant feasibility hurdles. The UK 
Government’s recent position on DCRs has 
become more accommodating to local agency 
(see Appendix 6.4), but this change in position 
does not address persisting legal barriers.
There are laws which would dictate how a DCR 
would operate and can be accommodated 
through management procedures, for example, 
not allowing service users to inject one another. 
There are then laws which would be difficult to 
overcome through service design. These are 
(Fortson, 2017 5):
–  Simple possession of the drug in question 
(e.g. traces on paraphernalia or drugs that are 
abandoned) 
–  Assisting or facilitating the drug user’s 
continued possession of the drug 
–  The conundrum of whether acts of drug 
preparation by the user constitute the 
‘production’ of the drug
–  Whether the occupier/manager of the DCR 
permits or suffers (with knowledge) the user to 
‘produce’ the drug on the premises 
–  Anti-smoking laws 
When Glasgow officials agreed to formally 
consider a DCR, two legal opinions were 
provided by two separate Queen’s Counsel to 
consider different legal routes. The legal opinion 
was privately commissioned and so is not 
available for public viewing, but was reportedly 
similar to legal opinions published by the Joseph 
Rowntree Foundation (2006), but see the 
updated paper by Fortson (2017). 
The chosen legal route for the Glasgow DCR 
was originally a discretionary model, rather than 
seeking to change legislation. There is flexibility 
within the law for the police to take a reasonable 
approach to law enforcement, exercising 
discretion in the public interest. The Health and 
Social Care Partnership viewed the discretionary 
model as a short-term solution to allow the 
operation of a pilot facility. If the evaluation of 
the service concluded that it was necessary and 
desirable in the longer term, a more permanent 
legal solution would have been sought through 
legislative change (Millar, 2017b). A change in 
prosecution policy was judged to be the more 
appropriate legal route in the first instance, as 
it would allow the facility to be established in 
less time than it would take to change legislation 
(Millar, 2017b). 
Guidance was sought from Scotland’s Lord 
Advocate, the chief legal officer of the Scottish 
Government and the Crown in Scotland for 
both civil and criminal matters that fall within the 
devolved powers of the Scottish Parliament, to 
allow an exemption from the relevant sections of 
the 1971 Misuse of Drugs Act (Millar, 2017b). 
The Lord Advocate did not approve an exemption 
in prosecution policy but has given a clear steer 
on the next stage in the legal process to allow 
Glasgow to proceed. This will involve working 
with the Scottish Government, which officials are 
already doing. NHSGGC has commented:
‘We are delighted to have the support 
of the Scottish Government to ensure 
the appropriate legal context is in place 
to support the implementation and 
sustainability of a Safer Drug Consumption 
Facility in Glasgow. We will work with the 
Scottish Government now with regards to 
the legislation change required.’  
 
Dr Saket Priyadarshi, Glasgow Associate 
Medical Director at Addiction Services 
NHSGGC
The Dublin DCR model is operating through 
legislative change since the passage of the 
Misuse of Drugs (Supervised Injecting Facilities) 
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Bill 2017. Irish drug laws are comparable to UK 
drug laws, with both countries passing a Misuse 
of Drugs Act in the 1970s, which include laws 
that would challenge the operation of a DCR.  
The Misuse of Drugs (Supervised Injecting 
Facilities) Bill 2017 addresses the legal  
barriers which the operational design could  
not surmount. 
To begin the process of changing the law,  
the Ana Liffey invoked the help of the Voluntary 
Assistance Scheme, a service run by the Bar of 
Ireland which offers pro bono legal assistance 
to vulnerable sections of society who often 
encounter difficulties in accessing the legal 
system. The Voluntary Assistance Scheme 
agreed to formulate a legal opinion for the Ana 
Liffey and draft DCR legislation, putting together 
a panel of barristers, including two senior 
counsel and six junior counsel. The expertise of 
the panellists included civil law, healthcare law, 
drug law, drafting legislation, debt delegating 
legislation, obligations of medical professionals, 
planning and DCR operational procedure. 
Through the legal opinion, the Voluntary 
Assistance Scheme was able to indicate what 
laws would challenge or prevent a DCR being 
established. The case could then be made that,  
if the draft legislation was enacted, all of the  
legal problems identified in the legal opinion 
would be remedied. 
In April 2015, Senator Aodhán Ó Ríordáin  
was appointed as Minister of State at the 
Department of Health, with responsibility  
for the National Drugs Strategy. Senator Ó  
Ríordáin agreed to lobby the Supervised  
Injection Bill during his time in office and 
succeeded in securing the agreement of  
the Government to begin processing the  
legislation in December 2015. When   
Senator Ó Ríordáin lost his seat in the 2016 
General Election, the legislation continued to 
be progressed by Minister for State, Catherine 
Byrne, who succeeded in passing the legislation 
in May 2017.  
Amending legislation was the preferred legal 
route as it was felt that a discretionary model 
would be unlikely to withstand a legal challenge 
and legislation would give the DCR the strongest 
legal standing. 
For the UK to provide DCRs with legislative 
protection, Fortson advises that amendments 
could be made to the ‘Misuse of Drugs 
Regulations Act’ or the UK could follow Ireland’s 
model of passing a ‘Misuse of Drugs (Supervised 
Injection Facilities) Act’. 
Other UK jurisdictions could follow a legal 
discretionary route by making an application for 
guidance from the Crown Prosecution Service 
for England and Wales or Public Prosecution 
Service for Northern Ireland. Such guidance 
would be susceptible to changes of policy and 
senior personnel within the police or prosecution 
service and is also vulnerable to legal challenge 
as the guidance would not have the force of law. 
However, the courts will not lightly interfere with 
the exercise of discretion that is reasonable and 
rational (Fortson, 2017). 
A discretionary model could operate without 
legal guidance from the prosecution service 
and instead rely solely on multi-agency support, 
with local stakeholders signing a document 
regarding the establishment and running of the 
DCR – whether styled as a ‘protocol’, ‘terms 
of engagement’ or ‘comfort letter’.  Though 
feasible, such a protocol would be exposed to 
the potential for political, legal and administrative 
challenges (Fortson, 2017 6).
Recommendation: There are legal barriers 
which would challenge the operation of a DCR 
in the UK. However, there is flexibility within the 
law for the police to take a reasonable approach 
to law enforcement, exercising discretion in the 
public interest. A DCR could operate through a 
discretionary model, pursuant to guidance given 
by the police and prosecution service. Such 
guidance would be susceptible to changes of 
policy and senior personnel within the police 
or prosecution service and is also vulnerable to 
legal challenge as the guidance would not have 
the force of law. However, the courts will not 
lightly interfere with the exercise of discretion 
that is reasonable and rational. Alternatively, 
a discretionary model could operate without 
legal guidance from the prosecution service 
and instead rely solely on multi-agency support, 
with local stakeholders signing a document 
regarding the establishment and running of the 
DCR. Though feasible, such a protocol would 
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be exposed to the potential for political, legal 
and administrative challenges. A legislative route 
entails a longer process but is a more stable  
and permanent legal solution. However, 
evaluations of a facility, operating on a 
discretionary model, could be used to  
build the case for legislative change.
5.4.2. International Community 
The international community plays a role in 
determining the legality of DCRs. In recent years, 
the International Narcotics Control Board (INCB), 
the body responsible for monitoring adherence to 
the United Nations Conventions, has expressed 
concerns about DCRs, but accepts that they can 
be consistent with the conventions if they ‘reduce 
the adverse consequences of drug abuse 
through treatment, rehabilitation and reintegration 
measures, without condoning or increasing 
drug abuse or encouraging drug trafficking’ 
(2016, p.91). INCB position statements from 
previous years have concluded that ‘consumption 
rooms are in violation of the provisions of the 
international drug control conventions’ (2012, 
p.100). One interviewee commented that the 
unfavourable position of the UN had coloured 
discussions surrounding the feasibility of 
establishing a DCR. 
However, the INCB position no longer cites 
concerns and now simply states:
‘For “drug consumption rooms” to be consistent 
with the conventions, they must aim at effectively 
reducing the negative consequences of drug 
abuse and lead to treatment and rehabilitation, 
without condoning or encouraging drug abuse 
and drug trafficking’ (INCB, 2017)
Interviewees from Glasgow and Dublin both 
confirmed that there has been no interference  
in proceedings from international bodies.  
Instead, both local areas found that the 
international community was a useful space  
for learning and guidance. 
The Glasgow process significantly benefited  
from its National Naloxone Coordinator t 
ravelling to Sydney to bring back operational  
and evidential learning from the Uniting  
Medically Supervised Injecting Centre,  
in video and report format (Horsburgh, 2015). 
‘I was able to bring back the learning  
from Sydney to key stakeholders and  
show a video about the service as 
well, which really helped people’s 
understanding of it. Certainly, I would  
say it definitely helped inform their 
opinions on it and bringing back that 
evidence was really useful. I also 
presented the evidence to the group 
that were working on the [local needs] 
assessment in Glasgow and was able  
to answer a lot of the questions they  
had on injecting facilities... If you’ve  
never been in an injecting room or  
don’t really know much about it, it’s  
quite difficult to get your head around, 
so being able to answer a lot of those 
questions was valuable and hopefully 
helped inform some of the learning  
for the needs assessment’.  
 
Kirsten Horsburgh, National Naloxone 
Coordinator, Scottish Drugs Forum
Similar work was undertaken by Ana Liffey, 
whose CEO Tony Duffin travelled to Sydney  
in March 2015 to meet with Dr Marianne  
Jauncey, the Medical Director at the Uniting 
Medically Supervised Injecting Centre,  
and other stakeholders involved at a policy  
level. Ana Liffey advised that it was essential  
for a local area to visit a facility if they were 
considering establishing a DCR, to address 
queries regarding operational guidance  
and stakeholder engagement. 
 
‘[In a] press conference we were  
asked questions about how [the DCR] 
would run, and if I hadn’t been there  
two months previously, I couldn’t  
have answered the questions as well  
as I did...I think you can train people  
up, you can have people visit you, you  
can do a course; but, if you’ve worked  
in a DCR, then you can refer back to  
those memories and experience to  
give a better informed answer.’  
 
Tony Duffin, CEO,  
Ana Liffey Drug Project
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Recommendation: The UN currently advises  
that DCRs are justifiable if they reduce the 
negative consequences of drug abuse and  
lead to treatment and rehabilitation, without 
condoning or encouraging drug abuse and 
drug trafficking. The international community 
has been a useful source of expertise to assist 
the developments in Dublin and Glasgow. By 
building relationships with their international 
counterparts, stakeholders can address 
questions regarding operational procedure  
and stakeholder engagement. 
5.4.3. Policing 
Though legal barriers can be surmounted,  
the area surrounding the facility would still  
need to be policed and the success of a  
DCR relies to a large extent on collaboration  
and strong working relationships with the  
police. Uncertainty over how a facility would  
be policed was cited as a significant obstacle  
in one locality.
In anticipation of facility’s establishment in 
Glasgow, a policing sub-group of the DCR 
short life working group has been established, 
chaired by Police Scotland, to advise on relevant 
public order issues and to develop working 
accords (MIllar, 2017c). Local police and service 
accords across the world have been reviewed 
and the Health and Social Care Partnership is  
considering which model of practice should be 
used, with any modifications if necessary.
Interviewees explained that it is expected that 
the police will continue with their normal policing 
activities, but there will be an understanding  
that they will not specifically target people who  
are travelling to the DCR. It is also anticipated  
that there will be established referral pathways  
between the police and the facility as the police  
are likely to discover people who would benefit  
from the facility, during their normal  
policing activities. 
Dublin is  in a more advanced legal position  
than Glasgow as legislation has been passed 
which clearly indicates what sections of the  
1977 Misuse of Drugs Act do not apply to a  
DCR service user. The legislation also grants  
the police powers to enter a DCR. 
Police discretion is still required, though Marcus 
Keane, a lawyer and Head of Policy at the Ana 
Liffey, explained that this model is likely to not be 
a significant departure from existing practice:
‘If I’m a police officer and I come  
across somebody I reasonably suspect  
to be in possession of a substance,  
I could in theory arrest them for 
possession. However, just because  
I can do it, doesn’t mean I have to do it. 
The police do not arrest everybody who 
they suspect to be guilty of some crime 
- if they did they would be completely 
inefficient and ineffective. The reality  
is that effective policing involves the  
use of discretion, not just in drugs law,  
but in many other areas also. In terms  
of a DCR, can police officers pull up 
outside and just wait to pick people up? 
Yes, of course they could, but they could 
do that anyway with many already existing 
locations. It’s not as if there aren’t people 
with drugs in the city centre as it stands 
and that we don’t know where those 
people with drugs go.’  
 
Marcus Keane, Head of Policy,  
Ana Liffey Drug Project
During the pre legislative scrutiny for Ireland’s 
Misuse of Drugs (Supervised Injecting Facilities) 
Bill, the police did see challenges ahead in how 
a DCR would be policed but promised ‘it will 
do all it can to assist in ensuring the initiative 
succeeds in achieving its objectives. Currently 
the police are visiting and observing the policing 
in jurisdictions where supervised injecting  
facilities have been in place for some time. 
Once the provisions of the Bill are enacted, 
the police will ‘inform its personnel regarding 
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the appropriate manner in which to address 
the law enforcement and policing issues which 
will arise following the opening of a supervised 
injecting facility. It will also facilitate the inclusion 
of relevant information in policing plans and 
operational orders’. The police have advised 
that clear legislation makes it less likely that ‘any 
law enforcement issue will impact negatively on 
achieving a successful outcome to the initiative’ 
(Joint Committee on Health, 2016). 
The police are committed to the success of the 
project, with Assistant Police Commissioner Pat 
Leahy, advising: 
‘Up and down main streets there are people who 
have heroin on them. Anything that can improve 
lives, I have to support. I cannot see any other 
way than treatment is the answer. We have to be 
mature about this’ (The Journal, 2017).  
UK police forces have recognised the need to 
take a holistic approach to drug issues, which 
‘supports the work of local agencies that aim 
to get users into treatment rather than pursue 
arrests for minor offences’ (DEFRA et al, 2005, 
p.7). Greater Manchester Police has stated that 
the force policy on those returning used needles 
to needle syringe programmes is that:  
“unless there are other attendant circumstances, 
officers will not arrest a person who is attending 
a needle exchange scheme, for the purpose 
of exchanging a needle.” It is recognised 
that a written instruction cannot cover all the 
circumstances likely to be encountered, however, 
officers should act according to the ‘intent’ of 
the policy, that is ‘not to arrest a person who is 
merely attending a centre to exchange a needle’  
(DEFRA et al, 2005, p.7)
In the context of needle and syringe programmes, 
it is recommended that an agreement or protocol 
is established between police and local agencies 
regarding the possession of used needles and 
their return, as it may be that trace amounts of 
illegal drugs are still present (DEFRA et al, 2005, 
p.7). Discretion is commonplace in policing and 
similar protocols could be put in place for DCRs.  
Recommendation: The success of a DCR relies 
to a large extent on collaboration and strong 
working relationships with the police. It is likely 
that police procedure will not be a significant 
departure from existing procedure for policing 
drug services but forces would benefit from 
observing models of practice in countries where 
DCRs have been in place for some time. Clear 
guidance or legislation would make it less likely 
that any law enforcement issue would impact 
negatively on the facility. 
5.4.4. Service Providers 
A DCR could be provided by the NHS but 
it is likely that part of the service, if not all of 
the service, will be commissioned to a third 
sector treatment provider. An operator who is 
supervising the use of illicit drugs on site is  
likely to be managing overdoses more regularly 
than in any other drug-related services. One 
interviewee doubted that there would be interest 
from third sector providers to run the service,  
as they would be taking on and managing too 
much risk. 
Contrary to this expectation, there have  
been high levels of interest from third sector 
providers in Glasgow and Dublin. It is intended 
that the Glasgow model will have three phases  
to the service:
–  Phase 1: Reception
–  Phase 2: Drug consumption room area
–  Phase 3: Aftercare area / additional  
support elements 
The June Integrated Joint Board update  
suggests that there is the potential for phase 
one and three to be provided by third sector 
organisations, with NHSGGC providing phase 
two. The update comments that ‘a number of 
partners from the third sector have expressed 
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interest in contributing to services provided 
within the proposed services’ (Millar, 2017b, p.2). 
The Dublin DCR may be run by a third sector 
provider with an invitation to tender sent by the 
Health Business Services in early September 
(2017). Bids were submitted from a range of 
third sector organisations and it is expected that 
the chosen organisation will be announced in 
December. 
Ana Liffey would argue that the risks a third 
sector drug addiction service would face when 
running a DCR are not new and may, in fact,  
be fewer in nature.
‘Addiction services take those risks all the 
time, working with people who use drugs. 
People aren’t allowed to be in possession 
of drugs, people aren’t allowed to use 
drugs on site. Are people in possession 
of drugs, do they use on site? Of course 
they do on occasion, so, addiction 
services are managing those risks at the 
moment - as are many, many services in 
all jurisdictions, so this is a safer way to 
work with people who use drugs. It brings 
it out of the toilets, out of the bedrooms 
of the hostels, into a space where people 
are talking to each other – removing the 
stigma and the reducing the risks to all.’  
 
Tony Duffin, CEO,  
Ana Liffey Drug Project 
Though the risks will be familiar to third sector 
providers, in Ireland there is also additional 
statutory protection for exempting liability, similar 
to Good Samaritan legislation, which protects 
the actions of persons who act in good faith. 
Liability of licence holder (section 9), Misuse of 
Drugs (Supervised Injecting Facilities) Bill 2017:
‘A licence holder or any person acting under 
the direction of the licence holder shall not be 
liable for any act done or omitted to be done in 
a supervised injecting facility, in relation to the 
provision of assistance or advice to, or care of, 
an authorised user and no person shall have a 
cause of action in respect of that act.’  
(House of the Oireachtas, 2017)
However, Ana Liffey advised that a provider 
should not bid to run a DCR unless there was  
a strong desire from within the organisation to  
do so.
‘Ideally, the whole organisation wants  
to do this… You’ve got to want to do this, 
right across the organisation. You’ve got 
to be excited about the idea of running the 
[DCR], you’ve got to have the competency 
to do it and the desire to do it.’  
 
Tony Duffin, CEO,  
Ana Liffey Drug Project
In the UK, numerous treatment providers have 
announced their interest in being the provider 
of a DCR, including CGL, Blenheim CDP and 
Collective Voice (on behalf of its members). Any 
service provider which does offer this service 
would benefit from positive media coverage 
and would be in a favourable position for future 
DCR tendering contracts, by having the unique 
experience of having run one elsewhere. 
Recommendation: The risks that come with 
supervising the use of illicit drugs on site are  
not dissimilar to existing risks taken by drug 
addiction services, which currently manage  
the consequences of unsupervised use of  
illicit drugs on site. Additional statutory 
protections can also be put in place which 
exempt liability, similar to Good Samaritan 
legislation. There have been high levels of 
interest by the third sector in being the  
service provider of a DCR in Dublin,  
Glasgow and elsewhere in the UK. 
5.4.5. Opening Hours 
A DCR brings many benefits to the local a 
rea where it is established but these benefits  
are most felt during the times that the service  
is open. Once the service closes, service  
users may continue to use drugs outside of the 
facility and potentially in a public setting. One 
locality struggled to arrive at a solution which 
could meet the expectations of local stakeholders 
and could feasibly be provided. 
In Glasgow, the opening hours of the DCR will 
be 9am-9pm. These times were decided upon  
as they ‘reflect known patterns of drug use within 
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the city and complement the availability of other 
supports, for example the requirement to be in 
hostel accommodation by 10pm’ (Millar, 2017b, 
p.6). Though it is likely people will still use drugs 
outside of these times, the opening hours will 
be meeting the need of the majority of PWUD 
in Glasgow city centre. Glasgow stakeholders 
advised that there are no ideal opening hours as 
the times should be guided by the local needs 
assessment. Equally though, this need has to be 
balanced against financial constraint and what 
the local area is capable of providing. 
Dublin opening hours were informed by a 
consultation with people who inject drugs in 
a street setting, with the invitation to tender 
suggesting that times are broken into brackets 
of 6:00-10:00, 14:00-17:00 and 20:00-22:30. 
Essential opening times are 6:00-10:00, to meet 
the needs of the vast majority of injectors who 
use at the beginning of the day (Health Business 
Services, 2017). Ana Liffey commented that in 
Dublin, there is typically  less need to have a 
DCR open throughout the night as service users 
would be sleeping and, if they did need to use, 
they would wake up, use where they are sleeping 
and then go back to sleep (see Appendix 6.2 and 
6.3 for further details on Glasgow and Dublin 
service designs). 
Recommendation: It is likely that drug 
consumption will continue outside of service 
hours, however, to minimise the extent to which 
this occurs, opening hours should be informed 
by a stakeholder consultation which identifies 
the times of greatest need. Equally though, 
recommendations have to be balanced against 
financial constraint and what the local area is 
capable of providing. 
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“DRUG CONSUMPTION ROOMS ARE 
NOW A VIABLE POLICY OPTION AND 
SERIOUS CONSIDERATION SHOULD 




The evidence indicates that DCRs can address 
rising drug-related harms and the developments 
in Dublin and Glasgow demonstrate their 
potential feasibility for a number of locations in 
the UK. DCRs are now a viable policy option and 
serious consideration should be given to their 
introduction. 
The unique element of a DCR that needs to 
be accommodated is its legal operation as 
there are some persisting legal barriers which 
would be difficult to overcome through service 
design. Legislative change offers a more stable 
and permanent legal solution but DCR pilots 
operating on a discretionary model could be 
used to build the case for legislative change.
UK drug laws also operate within the context 
of UN conventions. DCRs are consistent with 
current UN interpretations, as long as they aim to 
effectively reduce the negative consequences of 
drug use and lead to treatment and rehabilitation, 
without condoning or encouraging drug use and 
drug trafficking. 
However, the majority of cited concerns and 
barriers were not novel. They are frequently 
faced when commissioning drug addiction 
services and have repeatedly and successfully 
been answered and addressed. To ensure 
that a service has sufficient impact, a needs 
assessment should be undertaken, which 
identifies the location and opening hours that 
would see the service being sufficiently used, 
balanced with other considerations. This 
assessment can also make the case that a 
DCR is the most cost- effective solution to the 
drug-related harms experienced by the locality 
and can ground the business case within the 
needs of the local community, rather than on 
comparisons with other countries. The financial 
burden does not have to fall on one sector and 
funding for a DCR can be sourced through: 
central budgets, contingency funding, diversion 
from services targeted at the population who 
are likely to use the DCR, for example homeless 
addiction services, or diversion from services 
which would see savings as a consequence of 
the DCR being established. Politicians, media 
and local residents may raise objections to a 
DCR, and an engagement process would need 
to be targeted at  each of these groups. The 
case can be made that a DCR is consistent with 
the recovery agenda as, through the provision of 
a harm reduction service, the facility is offering 
recovery opportunities. New protocols would 
have to be formulated for police, but it is likely 
that this  will not be a significant departure from 
existing procedure for policing drug services. 
Equally, the risks that come with supervising the 
use of illicit drugs on site are not dissimilar to 
existing risks taken by drug addiction services, 
who currently manage the consequences of 
unsupervised use of illicit drugs on site. 
Stakeholders can learn from innovation in 
Glasgow and Dublin but can also turn to existing 
practice, realising that the way forward may not 
be a significant departure from well trodden 
paths. In some ways, DCRs are a sizable shift in 
existing provision but, mostly, they are simply an 
extension and do not require a ‘reinventing of the 
wheel’. By following in the footsteps of Glasgow 
and Dublin, but also turning to what is already 
known, localities will be best placed to replicate 





To find out current concerns and barriers that 
would prevent the establishment of a DCR in 
the UK, Volteface conducted 15  interviews 
with people in England and Wales who have 
advocated for DCRs, attempted to establish 
DCRs, or raised concerns surrounding their 
provision. Interviewees were contacted directly 
or sourced through Volteface’s network of 
contacts, with snowball sampling used to recruit 
further participants. Interviewees have been 
named in the acknowledgements, but were 
asked to anonymously contribute what they felt 
were the concerns which would prevent the 
establishment of a DCR. 
Interviewee contributions were collated and 
taken to 10  stakeholders in Glasgow and 
Dublin who have been named as playing a 
role in progressing the establishment of a 
DCR. The questions asked to Glasgow and 
Dublin interviewees were dependent on their 
specialisms, meaning different interviewees were 
asked different questions.  
As Glasgow is the UK locality which has made 
the most progression towards establishing 
a DCR, it is the most relevant case study for 
other UK localities to turn to for guidance on 
feasibility. Dublin is a particularly relevant case 
study, compared to recent DCR developments 
in other Western European countries, as the UK 
and Ireland have drug laws which prohibit similar 
activities, both introducing a Misuse of Drugs 
Act in the 1970s. The UK and Ireland also have a 
unique influence on one another due to a shared 
history and have seen a similar shift towards 
the decriminalisation of drug use (BBC, 2016a; 
Department of Health, 2017). Both countries 
have also seen people who use drugs experience 
persisting and increasingly poor health and 
injection-related harm (Long and Lyons, 2010; 
ACMD, 2016; EMCDDA and Health Research 
Board). Moreover, learning from Dublin is more 
accessible for UK counterparts as the two 
countries share a common language. 
As Glasgow and Dublin are working in 
different contexts and are at different stages 
in progressing the establishment of a DCR, 
they differ in how much they can comment on 
identified concerns.
7.2. Glasgow Service Design 
Service type: Injecting and inhalation
Length of pilot: Three years
Staffing per shift: To be confirmed
Annual cost: Estimated £1 million, final cost is 
dependent on site
Eligibility criteria: Those aged 16 and over who 
are consuming illicit drugs. Proof of age or 
pregnancy status is not required at registration. 
However, staff will be vigilant and trained to 
respond appropriately to anyone who appears 
ineligible to use the service.  
Opening hours: 9am-9pm, 7 days a week
Service design: 12 drug consumption booths, 
including a reception and aftercare area  
Provider: Reception and aftercare area provided 
by third sector, DCR area provided by the NHS. 
Operating procedures: Booths are for individual 
use only. Sharing or preparation and injection of 
one client by another is not permitted. Both of 
these practices constitute offences of “supply” 
under the Misuse of Drugs Act and under section 
23 of the Offences Against the Person Act. 
Alcohol consumption or cigarette smoking will 
not be permitted in the facility. 
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Additional services: Supplies of take home 
naloxone and injecting equipment, including the 
supply of foil to promote transition from injecting, 
will be available to clients on leaving the facility. 
Further preventative and supportive health,  
social care and peer support, including advice 
and referral to specialist treatment options  
can be accessed in the after-care area  
(Millar, 2017b). 
7.3. Dublin Service Design 
Service type: Injecting only
Length of pilot: 18 months 
Staffing per shift: Assessment area requires 
a minimum of one receptionist and one/two 
security person(s) at all times. The security 
person will manage front of service and stop 
people congregating.  
 
Annual cost: Estimated to be €1 million 
Eligibility Criteria: Eligibility guided by clinical 
decision, including access for under 18s and 
pregnant women
Eligibility Criteria: Eligibility guided by clinical 
decision, including access for under 18s and 
pregnant women. 
The injecting and clinical area requires three 
nurses to be on duty at all times, two registered 
nurses and one clinical nurse manager reporting 
through an appropriate nursing governance 
structure. A doctor is required to be on duty a 
minimum of five days per week, and for an overall 
minimum of 30 hours in total with their time split 
between the available sessions appropriately. 
The ‘chill out’ area requires a minimum of two 
project workers to provide support in relation to 
accessing ‘wrap around’ services. 
Opening hours: The facility will open from 6:00-
10:00 to meet the needs of the vast majority of 
injectors who use at the beginning of the day. 
The facility will also be open in the afternoon 
with suggested timings being 14:00-1700 and 
20:00-22:30 hours daily. Staggered or sessional 
opening is required to facilitate use prior to 
individuals returning to hostels at night.  
The service will open seven  days a week  
(Health Business Services, 2017). 
Service design: 
1.  An assessment and intake area where basic 
details of the service user can be obtained 
and the person is welcomed. Information 
on the DCR, house rules (for example  no 
dealing, sharing of drugs) and information 
on sterile injecting is provided and a basic 
health needs assessment is carried out. The 
area is of sufficient size to prevent ‘on-street 
congregation’ of people waiting to use the 
facility. The area is equipped with a reception 
desk and can seat between 10 to 15 people. 
2.  A clinical area comprising of six injecting 
booths where sterile injecting equipment can 
be distributed and supervised injecting can 
occur in a space protected from public view. 
Resuscitation equipment is available and the 
individual is monitored in case of overdose 
or adverse reactions. The area is equipped 
with a desk and chairs for nursing staff and a 
lockable cupboard for medical consumables.
3.  A relaxation or ‘chill out’ area where people 
can relax and be monitored for about 30 
minutes post- injection. The area is equipped 
with a self-service coffee/tea machine, 
comfortable chairs and small tables for service 
users. Space is available for project workers 
to interact with attendees and access to 
clinical rooms is readily available. 
Provider: Fully managed by a third sector 
provider or by the Health Service Executive
Operating procedures: The service will provide 
for adult (18+) established drug users who are 
on the premises of the supervised injecting 
facility with the permission of the licence holder, 
for the purposes of consuming drugs by injection 
only, during its normal opening hours. The facility 
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shall not be used for the consumption of drugs 
in any other manner, and such consumption of 
drugs by any other means (for example  smoking) 
is strictly prohibited. Sharing or dealing  drugs is  
not permitted at the facility. 
Additional services: Clinical rooms for medical 
interventions, crisis interventions, counselling 
interventions (if requested) and where referrals 
for social services/housing/treatment can occur. 
Specific medical clinics (e.g. bloodborne viral 
testing, vaccinations and wound and abscess 
care) will be available each day to allow 
individuals access to appropriate medical  
care. Naloxone training and distribution,  
and injecting equipment provision will be  
offered to individuals on leaving the facility.
7.4. A UK History of Drug  
Consumption Rooms 
While there is some history of unsanctioned  
DCR operation in the 1970s (Jolly, 2017),  
formal discussions did not start until 2002. 
2002: The Home Affairs Select Committee 
recommends that “safe injecting houses”  
(DCRs) should be piloted.
‘We recommend that an evaluated pilot 
programme of safe injecting houses for  
heroin users is established without delay  
and that if, as we expect, this is successful,  
the programme is extended across the country… 
We recommend that Section 8 of the Misuse  
of Drugs Act 1971 is amended to ensure that 
drugs agencies can conduct harm reduction 
work and provide safe injecting areas for  
users without fear of being prosecuted’  
(Home Affairs Committee, 2012, p.113). 
The recommendation is rejected by the 
Government which concludes that DCRs: 
‘should not be introduced in this country  
whilst we have no evaluations of those  
developed in other European countries.  
We would only consider contributing to a 
ny evaluation through the World Health 
Organisation in view of the uncertain legal  
status of injecting rooms. We would not wish 
 to consider any research initiative that could cause 
the UK to undermine the UN Conventions as that 
would not set a positive example to  
other signatories’ (Select Committee on  
Home Affairs, 2002).
2006: The Joseph Rowntree Foundation 
Independent Working Group on DCRs 
concludes, on the basis of a detailed review 
of feasibility and evidence, that ‘DCRs offer a 
unique and promising way to work with the most 
problematic users, in order to reduce the risk of 
overdose, improve their health and lessen the 
damage and costs to society. The IWG therefore 
recommends that pilot DCRs are set up and 
evaluated in the UK’ (2006, p.108).
The leader of the Conservative Party, David 
Cameron, responds by commenting that ‘I 
certainly wouldn’t rule them out because anything 
that helps get users off the streets and in touch 
with agencies that can provide treatment is worth 
looking at’ (The Guardian, 2006). 
However, the Independent Working Group’s 
recommendation is rejected. Parliamentary Under 
Secretary at the Home Office Vernon Coaker 
comments:
‘The reasons for rejecting it in 2002 are 
as valid today—the risk of an increase in 
localised dealing, anti-social behaviour 
and acquisitive crime’ 7 
  
(Womack, 2006).
April 2013: The Independent Drugs Commission 
for Brighton and Hove recommends that ‘the 
Safe in the City Partnership should convene 
a working group to explore the feasibility of 
implementing a form of consumption room, 
targeting those who are hard to reach and not 
engaged in treatment, as part of the range of 
drug services in the city’ (2013, p.10). 
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October 2013: The Home Office states that 
“The Government has no plans to allow drug 
consumption rooms, which [would break] laws 
whereby possession of controlled drugs is 
illegal” (The Independent, 2013).
May 2014: The Drug Consumption Room 
Feasibility Working Group concludes that a DCR 
in Brighton would not be feasible as there is 
insufficient local community need and a lack of 
support for a local accord (Wilkinson, 2013). 
October 2014: A Home Office review of 
international comparator approaches to drug 
misuse and addiction recognises the evidence 
of DCRs but does not recommend their 
implementation as ‘the UK does not experience 
open drug scenes of the kind which prompted 
the creation of the DCRs we saw in Switzerland 
and Denmark’ (Home Office, 2014, p.18). 
October 2016: The Glasgow City Integrated 
Joint Board approves the development of a full 
business case for a pilot DCR (BBC, 2016b). 
July 2017: The UK Government responds to the 
December 2016 ACMD recommendation that 
‘consideration is given – by the governments of 
each UK country and by local commissioners 
of drug treatment services – to the potential 
to reduce DRDs [drug-related deaths] and 
other harms through the provision of medically-
supervised drug consumption clinics in localities 
with a high concentration of injecting drug use’ 
(ACMD, 2016, p.40).
‘The Government has no plans to introduce 
drug consumption rooms. It is for local areas in 
the UK to consider, with those responsible for 
law enforcement, how best to deliver services 
to meet their local population needs. We are 
committed to taking action to prevent the 
harms caused by drug use and our approach 
remains clear: we must prevent drug use in our 
communities, help dependent individuals recover, 
while ensuring our drugs laws are enforced’  
(UK Government, 2017). 
The Government position no longer states that 
DCRs are illegal. The change of wording from 
its  2013 statement is also poignant, with it now 
stating that, ‘the Government has no plans to 
introduce drug consumption rooms’, rather than 
‘the Government has no plans to allow drug 
consumption rooms’. The most recent statement 
also alludes to the fact that decision-making 
surrounding DCRs should be devolved to the 
local levell
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1.  Various terms are used for the facilities, 
including drug consumption rooms, drug 
injection rooms, safe injecting centres, 
supervised consumption sites, safe injecting 
facilities, supervised injection facilities, safer 
consumption facilities, medically supervised 
injecting centres and enhanced harm reduction 
centres. Drug consumption room will be the 
preferred term for this report as it is widely 
used and encompassing of all terms. In the 
media, DCRs are commonly and incorrectly 
referred to as ‘shooting galleries’, facilities 
where users are expected to pay to use drugs 
on site, are unsanctioned by a national or local 
body and where medical supervisions is slight 
to non-existent (Fortson, 2017, p.3). Clients 
come to a drug consumption room with drugs 
they have already purchased, the facility does 
not supply them and operational procedures 
do not allow drug dealing on site.
2.  EMCDDA report that 90 DCRs operate 
in Europe (2017a). One DCR operates in 
Sydney, one operates in Montreal and four 
operate in Vancouver.
3.  This research preempts the EMCDDA’s 
recent recommendation ‘to identify and 
review the barriers to the establishment of 
drug consumption rooms in areas with high 
numbers of people injecting drugs in public 
places’ (2017b, p.56).
4.  Cardiff has not recorded drug-related litter prior 
to 2013/14. Erroneous data points have been 
deleted from Belfast and Leeds as it was evident 
that reporting procedures were not accurately 
capturing data. Drug-related litter in Liverpool is 
recorded annually, rather than by financial year. 
For the sake of clarity, the year beginning each 
financial year has been included.
5.  Directly draws on the legal opinion written by 
Rudi Fortson QC, detailing the legal issues of 
setting up a drug consumption room. Fortson’s 
document is intended only for guidance 
and discussion and he advises that anyone 
contemplating setting up a drug consumption 
room should first seek independent professional 
guidance (2017).
6. For more guidance, please see Fortson (2017)
7.  It should be noted that localised dealing, 
anti-social behaviour and acquisitive crime 
were not cited in the Government’s rejection 
of the Home Affairs Select Committee 
recommendation in 2002. The evidence does 
not suggest that DCRs lead to an increase in 
drug dealing, drug trafficking or drug-related 
crime in the surrounding environment.
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